Kalaris Therapeutics, Inc. Common Stock KLRS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Liquidity | |||||
| Current ratio | 12.2×+12.1× | 0.1×-6.5× | 6.6×-3.4× | 10×+3.3× | |
| Leverage | |||||
| Debt-to-equity | 0×— | —— | —— | 0.2×0.0× | |
| Per Share | |||||
| Book value per share | $5.16+107% | -$72.32-627% | -$9.95-440% | $2.93-18.4% | |
| Valuation | |||||
| Market capitalization | $96.83M+136% | —— | —— | —— | |
| Price / book | 1.6×+0.7× | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kalaris Therapeutics, Inc. Common Stock's ratios come from?
- Every ratio is computed from Kalaris Therapeutics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.